Flozins — in the light of the latest recommendations


Marta Wróbel, Dominika Rokicka, Krzysztof Strojek

Flozins (SGLT-2 inhibitors)  have been used in the treatment of diabetes since 2012. These drugs were initially approved for the treatment of type 2 diabetes as monotherapy if metformin was contraindicated or not tolerated, or in combination with other drugs and insulin if therapy intensified. Often in Polish conditions, the role of flozins was reduced to their use as a third-line drug added to metformin and a sulfonylurea. This was a recent attempt to intensify oral therapy in patients with type 2 diabetes who were not adequately compensated before the decision to switch to insulin. Recent years have shown additional benefits resulting from the use of flozins . This resulted in a change in the position of this group of drugs (ex aequo with metformin as first-line) in the type 2 diabetes treatment regimen in the recommendations of many recognized diabetes societies, including the Polish Diabetes Society. In addition, these drugs have strengthened their position in the treatment of diseases other than diabetes.

Full publication in Endokrynologia Polska »